异环磷酰胺、依托泊苷、顺铂联合治疗SCLC的疗效

Isofamide plus etoposide and cisplatin combined therapy in the treatment of small cell lung cancer

目的 观察含国产异环磷酰胺 (IFO)与依托泊苷 (VP 16)和顺铂 (DDP)联合治疗小细胞未分化癌SCLC疗效和毒性。方法 符合治疗条件SCLC16例 ,给予VIP方案化疗 :IFO1.5g/m2 ivd1～ 5,IFO注射后Mesna ,0 .4,8小时各 1次 ,VP 1610 0mgivd1～ 5,DDP 3 0mg/m2 ivd1～ 5或 80～ 10 0mg/m2 ivd1,水化 ,每 3周重复 ,局限期者 2～ 3周期化疗后辅以胸部病灶野和纵隔野放疗。结果 16例病人中 ,CR 8例 ( 5 0 % ) ,PR6例 ( 3 7.5 % ) ,CR +PR87.5 %。主要不良反应为骨髓抑制和消化道反应。结论 VIP方案治疗SCLC有效率高 ,在G CSF支持治疗下 ,骨髓抑制毒性反应可以耐受。

? Objective To observe the activity and toxicity of VIP regimen in the treatment of small cell lung canccr(SCLC).Methods 16 patients with SCLC received VIP regimen chemotherapy:IFO 1.5g/m 2iv d 1～5 ,Mesna 0.4g iv following IFO 0,4 and 8h VP 16 100mg iv d 1～5 , DDP 30mg/m 2 iv d 2～4 or 80～100mg/m 2 d 1 iv ,repeated every 3～4 weeks.In patients with limited loci adjuvant chest irradiation were given following 2～3 cycles of chemotherapy.Results Total remission rate was 50%(8/16),the partial remission rate was 37.5(6/16),RR was 87.5%(14/16).The most comon side effects were myelosuppression.nausea and vomiting.Conclusions VIP regimen is the most effective in the treatment of SCLC and toxicity of myelosupression is well tolerated in combination with G CSF. 〔